Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1983 Sep;16(3):344–345. doi: 10.1111/j.1365-2125.1983.tb02175.x

Effect of age and plasma concentrations of albumin and alpha 1-acid glycoprotein on protein binding of disopyramide.

D W Holt, A M Hayler, G F Healey
PMCID: PMC1428016  PMID: 6626430

Full text

PDF
344

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Cunningham J. L., Shen D. D., Shudo I., Azarnoff D. L. The effects of urine pH and plasma protein binding on the renal clearance of disopyramide. Clin Pharmacokinet. 1977 Sep-Oct;2(5):373–383. doi: 10.2165/00003088-197702050-00004. [DOI] [PubMed] [Google Scholar]
  2. David B. M., Madsen B. W., Ilett K. F. Plasma binding of disopyramide. Br J Clin Pharmacol. 1980 Jun;9(6):614–618. doi: 10.1111/j.1365-2125.1980.tb01090.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  3. Ehrnebo M., Agurell S., Jalling B., Boréus L. O. Age differences in drug binding by plasma proteins: studies on human foetuses, neonates and adults. Eur J Clin Pharmacol. 1971 Sep;3(4):189–193. doi: 10.1007/BF00565004. [DOI] [PubMed] [Google Scholar]
  4. Hinderling P. H., Garrett E. R. Pharmacokinetics of the antiarrhythmic disopyramide in healthy humans. J Pharmacokinet Biopharm. 1976 Jun;4(3):199–230. doi: 10.1007/BF01063614. [DOI] [PubMed] [Google Scholar]
  5. Holt D. W., Walsh A. C., Curry P. V., Tynan M. Paediatric use of mexiletine and disopyramide. Br Med J. 1979 Dec 8;2(6203):1476–1477. doi: 10.1136/bmj.2.6203.1476-a. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Karim A., Kook C., Novotney R. L., Zagarella J., Campion J. Pharmacokinetics and steady-state myocardial uptake of disopyramide in the dog. Drug Metab Dispos. 1978 May-Jun;6(3):338–345. [PubMed] [Google Scholar]
  7. Lindup W. E., Orme M. C. Clinical pharmacology: plasma protein binding of drugs. Br Med J (Clin Res Ed) 1981 Jan 17;282(6259):212–214. doi: 10.1136/bmj.282.6259.212. [DOI] [PMC free article] [PubMed] [Google Scholar]
  8. Meffin P. J., Robert E. W., Winkle R. A., Harapat S., Peters F. A., Harrison D. C. Role of concentration-dependent plasma protein binding in disopyramide disposition. J Pharmacokinet Biopharm. 1979 Feb;7(1):29–46. doi: 10.1007/BF01059439. [DOI] [PubMed] [Google Scholar]
  9. Piafsky K. M., Borgá O., Odar-Cederlöf I., Johansson C., Sjöqvist F. Increased plasma protein binding of propranolol and chlorpromazine mediated by disease-induced elevations of plasma alpha1 acid glycoprotein. N Engl J Med. 1978 Dec 28;299(26):1435–1439. doi: 10.1056/NEJM197812282992604. [DOI] [PubMed] [Google Scholar]
  10. Piafsky K. M., Borgå O. Plasma protein binding of basic drugs. II. Importance of alpha 1-acid glycoprotein for interindividual variation. Clin Pharmacol Ther. 1977 Nov;22(5 Pt 1):545–549. doi: 10.1002/cpt1977225part1545. [DOI] [PubMed] [Google Scholar]
  11. Routledge P. A., Shand D. G., Barchowsky A., Wagner G., Stargel W. W. Relationship between alpha 1-acid glycoprotein and lidocaine disposition in myocardial infarction. Clin Pharmacol Ther. 1981 Aug;30(2):154–157. doi: 10.1038/clpt.1981.141. [DOI] [PubMed] [Google Scholar]
  12. Rylance G. Prescribing in infancy and childhood. Br J Hosp Med. 1979 Oct;22(4):346-8, 351, 353-4. [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES